ORBCEL™ for ARDS
Acute Respiratory Distress Syndrome (including COVID-19 related)
Phase 1/2Active
Key Facts
Indication
Acute Respiratory Distress Syndrome (including COVID-19 related)
Phase
Phase 1/2
Status
Active
Company
About Orbsen Therapeutics
Orbsen Therapeutics is a private, clinical-stage biotech developing immunomodulatory cell therapies for serious conditions with high unmet need, including Diabetic Kidney Disease (DKD) and Acute Respiratory Distress Syndrome (ARDS). Its lead candidate, ORBCEL™, is a purified MSC therapy designed to target specific immune pathways driving inflammation and fibrosis. The company has advanced ORBCEL™ into Phase 2 clinical trials, supported by significant non-dilutive EU grant funding, and is actively fundraising to progress its pipeline. Orbsen operates from a new headquarters in Galway, positioning itself at the forefront of next-generation cell therapy.
View full company profile